In June 2024, Kunming Pharmaceutical Group Co., Ltd. announced that Mr. Wu Wenduo has resigned as Chairman of the Board due to personal reasons. According to the company’s statement, his departure will not disrupt the normal operations of the board, and his duties will be temporarily assumed by the Vice Chairman or another director until a new chairman is elected. During his tenure, Wu played a pivotal role in advancing the company’s strategic transformation, strengthening R&D innovation, and expanding into international markets. He spearheaded several key mergers, acquisitions, and partnerships that accelerated Kunming Pharma’s evolution into a globally oriented pharmaceutical enterprise. This leadership change comes at a critical juncture as the company deepens its state-owned enterprise reforms and refines its corporate governance structure. Market observers are closely watching for any shifts in management strategy or direction. The company reaffirmed its commitment to a development path centered on ‘core business focus and innovation-driven growth,’ aiming to ensure operational stability and sustainable expansion. Investors should monitor upcoming board appointments and the selection of a new chairman to assess continuity in corporate governance and strategic execution.
2024年6月，昆药集团股份有限公司发布公告，宣布吴文多先生因个人原因辞去公司董事长职务。根据公告，吴文多的辞职不会影响公司董事会正常运作，其职位将由副董事长或其他董事暂时代行，直至新任董事长选举产生。吴文多自担任昆药集团董事长以来，在推动企业战略转型、强化研发创新以及拓展国际市场方面发挥了重要作用。他主导了多项关键并购与合作项目，助力昆药加快向国际化医药企业迈进。此次人事变动正值昆药集团深化国企改革、优化治理结构的关键阶段，市场普遍关注其后续管理层调整及战略方向是否延续。公司表示，未来将继续坚持“聚焦主业、创新驱动”的发展路径，确保经营稳定和可持续增长。投资者需密切关注董事会换届进展及新任董事长人选，以判断公司治理和战略执行的连续性。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/8867.html